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Abstract
This paper concerns inference in instrumental variable models with a high-dimensional set of cor-
related weak instruments. Our focus is motivated by Mendelian randomization, the use of genetic
variants as instrumental variables to identify the unconfounded effect of an exposure on disease. In
particular, we consider the scenario where a large number of genetic instruments may be exogenous,
but collectively they explain a low proportion of exposure variation. Additionally, we assume that
individual-level data are not available, but rather summary statistics on genetic associations with the
exposure and outcome, as typically published from meta-analyses of genome-wide association studies.
In a two-stage approach, we first use factor analysis [8, 7] to exploit structured correlations of genetic
instruments as expected in candidate gene analysis, and estimate an unknown vector of optimal instru-
ments [9]. The second stage conducts inference on the parameter of interest under scenarios of strong
and weak identification. Under strong identification, we consider point estimation based on minimiza-
tion of a limited information maximum likelihood [1, 36] criterion. Under weak instrument asymptotics
[44], we generalize conditional likelihood ratio [34] and other identification-robust statistics [31, 3] to
account for estimated instruments and summary data as inputs. Simulation results illustrate favourable
finite-sample properties of the factor-based conditional likelihood ratio test, and we demonstrate use
of our method by studying the effect of interleukin-6 signaling on glycated hemoglobin levels.
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1 Introduction
1.1 Motivation
Mendelian randomization (MR) exploits exogenous genetic variation within a population to examine the
unconfounded effect of an exposure on outcome. For brevity, we refer to this parameter as the causal effect,
and it is of inferential interest. The immediate attraction of the MR approach is that genetic instruments,
which are fixed at conception, are considered inherently independent from environmental factors that
typically threaten the validity of instrumental variable (IV) analyses of many observational studies.
An emerging area of clinical research concerns MR studies with genetic instruments drawn from gene
regions of pharmacological interest. The effect of a drug can be studied by an MR analysis of a genomic
locus (cis-MR) encoding protein targets of medicines, see for example, [29, 52, 24], which can provide
valuable evidence to inform efficient design of expensive randomized control trials [23].
Figure 1.1. Direct acyclic graph of IV assumptions. Genetic variants are associated with the exposure (IV.1, relevance), not
associated with unobserved confounders (IV.2, exogeneity), and have no direct pathway to the outcome (IV.3, exclusion).
Furthermore, cis-MR approaches that integrate expression data, with proteins acting as the exposure,
are more likely to satisfy the exclusion restriction required for instrument validity [41]. The exclusion
restriction requires that any association between instruments and the outcome is only through their effects
on the exposure, which is plausible when the exposure is a direct biological product of the instrument.
The use of cis-MR for drug target study informs certain characteristics of genetic instruments. First, they
are likely to be in highly structured correlation, owing to how genetic variants in the same region tend to
be inherited together. Secondly, given that the process of identifying drug targets is often exploratory in
nature, MR analyses may be prone to the use of genetic instruments that are best only weakly associated
with the exposure. A weak association between instruments and the exposure can cause problems in terms
of identifying the causal effect; this is referred to as weak identification.
A further complication facing most cis-MR drug target analyses is that typically only summarized data is
available. While privacy and data-storage issues prevent dissemination of individual-level data from large-
scale genome-wide association studies (GWASs), summary statistics of marginal associations between
genetic instruments and a wide range of traits have now been made publicly available. This presents a
rich data source of association information of many instruments with structured covariance.
The statistical challenge for utilizing the potential of cis-MR is therefore the provision of reliable esti-
mators and tests that: (i) incorporate information from a high-dimensional set of correlated instruments;
(ii) are valid under weak identification of the causal effect; (iii) are operational with summary statistics
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comprising marginal associations of instruments and endogenous variables, and a sample covariance matrix
of instruments.
1.2 Related literature
In a weak instruments setting, commonly-used point estimators and their associated test statistics have
non-standard limiting distributions which cannot be consistently estimated [48]. Although the problems
resulting from weak instruments [48, 5] are widely understood in MR [16], there has been limited progress
in developing methods to address them. In MR studies, genetic instruments are usually collected genome-
wide, with instrument selection determined by the strength of association with the exposure or outcome.
This practice may more generally be linked to a wider trend of researchers conducting pre-selection tests
with the view to retaining only those instruments that are demonstrably relevant. Following Staiger and
Stock [44]’s rule-of-thumb detection of weak instruments, IV regression results with first-stage F-statistics
less than 10 may often be unreported in applied work; see Andrews et al. [5], p.729.
Unfortunately, pre-selection of instruments based on their strength results in biased estimates of the causal
effect when using traditional methods, and size distortions in their associated tests [61]. This source of
bias is called the winner’s curse in genetics [25], and has been shown to be damaging for MR analyses
[17, 51]. Recent MR developments have sought to appropriately adjust for the winner’s curse bias in
models with mutually independent instruments [11]. Sample-splitting approaches are also likely to reduce
instrument selection biases [12], and depending on the selection method, rate restrictions linking sparsity
of relevant instruments to sample sizes can allow valid inference in high-dimensional IV models; see, for
example, [10]. For our focus, sparsity restrictions are difficult to verify; there is a lack of clear separation
between relevant and irrelevant instruments due to highly structured correlations, and their weak effects
on endogenous variables.
One way to avoid a winner’s curse bias in cis-MR is to avoid instrument selection altogether, potentially
resulting in the inclusion of hundreds or thousands of correlated genetic instruments in an MR analysis.
Previous work has shown that dimension-reduction of instruments through principal components analysis
(PCA) [9, 43, 19, 20] can improve efficiency of estimation. To this end, Burgess et al. [18] develop a principal
components-based IV (IVWPC) estimator that is computable with summary statistics. However, we show
that its finite-sample performance may be of concern, especially with weak instruments.
Valid inference under weak instruments is provided by so-called identification-robust methods. Condition-
ally pivotal test statistics are compared against appropriate critical values which are also conditional on
a sufficient statistic for instrument strength under the null hypothesis [34]. For parameter estimation,
identification-robust methods abandon the pursuit of point estimates in favour of confidence regions ob-
tained by test inversion. In particular, for a nominated significance level, a confidence region of the causal
effect is given by the set of effect values that a test does not reject the null hypothesis.
While identification-robust tests are designed to control type I error under weak instruments, competitive
power requires incorporating identifying information in order to better detect violations of the parameter
restrictions under examination. Consequently, the well-known identification-robust test of Anderson and
Rubin (AR) [1] has relatively poor power properties in over-identified models, as compared with Kleiber-
gen’s Lagrange multiplier (LM) test [31, 32] and Moreira’s conditional likelihood ratio (CLR) test [34].
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Theoretical results arm the CLR test with near-optimal power properties [3, 2], which have been reflected
in simulation performance with individual-level data [34, 5, 4] and in a summary statistics framework [53].
1.3 Scope of this paper
This paper introduces methods for cis-MR inference with summary statistics under strong and weak
identification of the causal effect. Following Bai and Ng [9], the optimal instruments are assumed to
be latent factors of the observable instruments that must be estimated as a first stage. Given strong
correlation structure in the instrument covariance matrix, the observable instruments are modeled by an
approximate factor model [8] such that the optimal instruments are identifiable only up to a rotation
matrix (see Bai [7]). Our approach is therefore fundamentally different from existing summary statistics
MR approaches that have studied inference under many weak instruments [59, 11, 58, 53], but not inference
with a high-dimensional set of correlated weak instruments, as typically encountered in cis-MR studies.
For point estimation under strong identification of the causal effect, we construct a LIML estimator based
on estimated factor-based instruments and summary statistics (F-LIML). The asymptotic distribution of
the estimator is derived, which is used to construct standard errors and confidence intervals. In a simulation
study, we show that F-LIML estimates and standard errors are accurate when instruments are strong, and
we demonstrate finite-sample advantages over the IVWPC estimator.
When the finite-dimensional vector of optimal instruments is weakly associated with the exposure, un-
der similar weak instrument asymptotics studied in Staiger and Stock [44], we introduce versions of
identification-robust CLR, LM, and AR test statistics that account for factor-estimated instruments and
summary statistics. The tests control type I error, and their finite-sample power under varying instru-
ment strength is illustrated by simulation using genetic data. In general, the factor-based CLR test is
well-powered in scenarios of strong and weak identification, and yields confidence sets that are as accurate
as confidence intervals from LIML point estimation under strong identification. Thus, our work provides
evidence that the CLR test with factor-estimated instruments may be recommended for use in cis-MR
analyses.
Finally, we apply our method to a cis-MR study of potential therapeutic interest. Interleukin 6 Receptor
(IL6R) signaling is a pathway involved in inflammation. Higher IL6R signaling has been speculated to
worsen glycaemic control and increase risk of diabetes [33, 50]. By instrumenting circulating IL6R levels
(which inversely relate to IL6R signaling) with genetic variants at the IL6R gene, our analysis provides
evidence to support this hypothesis.
Proofs of our asymptotic results are given in the appendix.
2 Instrumental variables and approximate factor models
2.1 Approximate factor IV model (Bai and Ng [9])
We define genetic factors as unobservable variables f = (f (1), ..., f (r))′ which comprise the information
of any systematic variation in a set of highly correlated instruments Z taking values z = (z(1), ..., z(p))′.
The number of instruments (which are individual genetic variants in MR) p is considered to be very large
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relative to the number of factors r. For an exposure X taking values x, and an outcome Y taking values
y, we consider the reduced form IV model
y = β′Y f + eY
x = β′Xf + eX
βY = θ0βX , (2.1)
where the errors satisfy E[eY |f ] = 0, E[eX |f ] = 0, E[e2Y |f ] = σ2Y , E[e2X |f ] = σ2X , βX and βY are r-vectors of
effects sizes, and E[.] denotes the expectation taken with respect to the exposure, outcome, and instruments
(x, y, z). The parameter of interest is the causal effect θ0. Intercept coefficients are not included in the
model because, without loss of generality, it can be assumed that the summary data reported from marginal
x on z(k) regressions (likewise, y on z(k) regressions, for k = 1, ..., p) is based on mean-centred data, cf.
[60, 55].
The set of instruments are assumed to follow an approximate factor model structure [8, 7],
z = Λf + e, (2.2)
where Λ = (λ(1), ..., λ(p))′ is an unobserved p × r matrix of factor loadings, and e = (e(1), ..., e(p))′ is a
p-vector of idiosyncratic errors. Therefore, the component λ(k)′f describes the systematic variation in any
k-th instrument. The assumptions maintained in an approximate factor model are weak enough to prevent
separate identification of factors f and factor loadings Λ, however both can be estimated up to a r × r
rotation matrix. This is sufficient for accurate inference on the causal effect since in order to exploit the
explanatory power of the optimal instruments, we only require that the estimated factors span the same
space as the true factors [7, 9].
For our applied focus of cis-MR, this framework is agnostic regarding the genetic architecture characterizing
causal links between individual genetic instruments and outcomes.
2.2 Available summary data
For every instrument k = 1, ..., p, we observe the marginal regression results of endogenous variables on
instrument k as commonly reported from GWASs [14, 13]. For the exposure, we assume the availability
of estimated effect sizes bˆX = (bˆ
(1)
X , ..., bˆ
(p)
X )
′ and estimated standard errors σˆmX = (σˆ
(1)
mX , ..., σˆ
(p)
mX)
′ from
marginal x on z(k) linear regressions. For the outcome, bˆY = (bˆ
(1)
Y , ..., bˆ
(p)
Y )
′ and σˆmY = (σˆ
(1)
mY , ..., σˆ
(p)
mY )
′
are defined analogously.
The instrument-exposure and instrument-outcome association studies are assumed to be conducted in
mutually independent samples; {bˆY , σˆmY } are computed from an nY -sample {z˙i, yi}nYi=1, and {bˆX , σˆmX}
are computed from an nX -sample {z¨i, xi}nXi=1. We also require the availability of a sample instrument
covariance matrix computed from a reference sample {zi}nZi=1 of size nZ , see, for example, [60]. For genetic
instruments, popular software packages offer commands to import correlation matrices from samples such
as 1000-Genomes [28, 57], which can be combined with instrument variance estimates. The UK Biobank
study further provides individual-level data of genetic instruments which can be used to directly estimate
covariances.
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All samples from each of the three summarized datasets are assumed to be drawn from the joint distribution
of (x, y, z); the notation z˙ and z¨ clarifies that data from the nX -sized and nY -sized association studies are
obtained from two distinct random samples.
2.3 Assumptions
This section formally clarifies the model assumptions maintained for our asymptotic results. Assumption
2.1 is stated for a hypothetical sample {xi, yi, zi}ni=1 with the understanding that the restrictions apply to
all data sources. The following abbreviations are used:
P→: ‘converges in probability to’; D→: ‘converges
in distribution to’; ⊗ is the Kronecker product; ‖.‖ is the Euclidean norm for vectors, and the Frobenius
norm for matrices. Throughout, let C denote a sufficiently large, bounded constant.
Assumption 2.1 (approximate factor model - Bai [7]).
(i) the unobserved factors {fi}ni=1 and idiosyncratic errors {e(k)i }ni=1 are i.i.d, (k = 1, ..., p);
(ii) E[‖f‖4] ≤ C, and E[ff ′] is a r × r positive definite matrix;
(iii) ‖λ(k)‖ ≤ C, (k = 1, ..., p), and 1pΛ′Λ
P→ ΣΛ, an r×r positive definite, non-random matrix, as p→∞;
(iv) E[e(k)] = 0, and E[|e(k)|8] ≤ C, (k = 1, ..., p);
(v)
∑p
k=1 |E[e(k)e(l)]| ≤ C; (l = 1, ..., p);
(vi) E[| 1√p
∑p
k=1(e
(k)
i e
(k)
j − E[e(k)i e(k)j ])|4] ≤ C, (i, j = 1, ..., n; k = 1, ..., p);
(vii) E[‖ 1√p
∑p
k=1 λ
(k)e
(k)
i ‖2] ≤ C, E[‖ 1√n
∑n
i=1 fie
(k)
i ‖2] ≤ C, E[‖ 1√p
∑p
k=1 fi(e
(k)2
i − E[e(k)2])‖2] ≤ C,
and E[‖ 1√np
∑n
i=1
∑p
k=1 fie
(k)
i λ
(k)′‖2] ≤ C, (i = 1, ..., n; k = 1, ..., p).
Assumption 2.1 imply Assumptions A-F from Bai ([7], pp.141-4) since we impose an i.i.d. structure on
factors and idiosyncratic errors; we will assume the reference sample on instruments and the two association
studies are based on i.i.d. sampling. Assumptions 2.1(ii), (iii) imply that there exist r factors. A feature
of this restriction is that for the population instrument covariance matrix E[zz′], there will be a significant
separation between the r-th and (r + 1)-th largest eigenvalues of E[zz′]; see Figure 5.1 in Section 5.1 for
an illustration of this requirement. This could be considered innocuous for cis-MR applications. Genetic
variants (instruments) are only considered for the analysis if they are contained within the gene region of
interest. As a result, when a large enough number of genetic variants have been sourced, an additional
variant from the same region is likely to be correlated with one that is already included.
Regarding restrictions on the idiosyncratic errors, Assumptions 2.1(v)-(vii) permit weak cross-sectional
dependence across instruments. This could be weakened further to also permit weak dependence across
individuals as in Bai [7], which would allow the possibility of overlapping individuals that have participated
in two studies, but we do not pursue that in our analysis here. Factors (similarly, factor loadings) can
also be dependent on the extent to which Assumption 2.1 holds. Assumption 2.1(vii) corresponds to
Assumption F of Bai ([7], p.144), and can be satisfied by standard conditions required for central limit
theorems.
Assumption 2.2 (linear IV model with factor instruments).
(i) E[|x|2] <∞, E[|y|2] <∞, and |z(k)| < C, (k = 1, ..., p);
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(ii) y = f ′βXθ+ eY and x = f ′βX + eX , uniquely at θ = θ0, E[eY |f ] = 0, E[eX |f ] = 0, E[e2Y |f ] = σ2Y , and
E[e2X |f ] = σ2X ;
(iii) βX is a fixed, non-zero vector.
Assumptions 2.1(ii), 2.2(ii), and 2.2(iii) imply that the r-vector of optimal instruments f are robustly
associated with the exposure and allow point identification of the true parameter θ0 in the IV model.
While these latent factors f are assumed to be strong instruments, this does not prevent many individual
instruments in {z(1), ..., z(p)} from having weak or zero factor loadings and consequently weak association
with the exposure ([9], pp.1581-2). The case where the optimal instruments f are weak is outlined in As-
sumption 2.4. The boundedness conditions in Assumption 2.2(i) are trivially satisfied in most applications;
for example, the vector of genotypes z are discrete variables taking values {0, 1, 2}.
Assumption 2.3 (summary association data and instrument validity).
(i) {yi, z˙i}nYi=1, {xi, z¨i}nXi=1, and {zi}nZi=1 are i.i.d. samples taken from the joint distribution of (x, y, z);
(ii) quantities Dˆ
(k)
X , Dˆ
(k)
Y , and Dˆ
(k)
Z , accurately estimate sample instrument variances D¨
(k)
X =
1
nX
∑nX
i=1 z¨
(k)
i ,
D˙
(k)
Y =
1
nY
∑nY
i=1 z˙
(k)
i , and D˜
(k)
Z =
1
nZ
∑nZ
i=1 z
(k)
i , to orders oP (n
− 12
X ), oP (n
− 12
Y ), and oP (n
− 12
Z ), respectively,
(k = 1, ..., p);
(iii) (nY /nX)→ cXY and (nZ/nY ) 6→ 0, as nX →∞, nY →∞, and nZ →∞, for some unknown positive
constant cXY <∞;
(iv) for u = y − θ0x and γ(k) = E[e(k)u], either
∑p
k=1 |γ(k)|2 ≤ C and nY
/
p2 → 0, or ∑pk=1 |γ(k)|2 = 0
and nY
/
p2 6→ 0;
(v) E
[∥∥ 1√
nY p
∑p
k=1
∑nY
i=1 λ
(k)(e˙
(k)
i yi − E[e(k)y])
∥∥] ≤ C;
(vi) E
[∥∥ 1√
nXp
∑p
k=1
∑nX
i=1 λ
(k)(e¨
(k)
i xi − E[e(k)x])
∥∥] ≤ C.
By Assumption 2.3(i), samples from each of the three data sources are exchangeable which, in the context
of genetic epidemiology, implies they are sampled from within the same geographical region using common
selection criteria. Assumption 2.3(iii) ensures the sampling variability of each genetic or genome-wide
association study is taken into account, however it is not restrictive since cXY is unknown and only
required to be positive. Assumption 2.3(ii) implies the sampling errors from estimation of instrument
sample variances are not taken into account, which is often justified in MR practice by large sample sizes
(see, for example, Assumption 1 of [59], p.3).
Estimates of instrument sample variances may be constructed in various ways. For example, given knowl-
edge of sample variance of the exposure ˆvar(X), D¨
(k)
X can be directly calculated using the linear regression
summaries bˆ
(k)
X and σˆ
(k)2
mX as D¨
(k)
X = ˆvar(X)
/
(nX σˆ
(k)2
mX + βˆ
(k)2
X ). Alternatively, GWAS summary data often
report minor allele frequencies of genetic instruments, which provide information on the prevalence of
genetic variants in a population, and can be used to construct instrument variance estimates assuming
Hardy-Weinberg equilibrium. Finally, for the reference sample, direct calculations of instrument variances
are also possible given access to individual-level data, for example, from the UK Biobank.
Assumption 2.2(ii) implies that the r instrument factors f are valid instruments, but it does not imply
all p instruments z are valid. Following Bai and Ng [9], we can allow for some genetic instruments to be
invalid, where the k-th instrument is necessarily invalid if γ(k) 6= 0. To see this, by Assumption 2.2(ii) we
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have E[fu] = 0, so that γ(k) 6= 0 implies E[z(k)u] 6= 0, which violates a necessary orthogonality condition
required for instrument validity.
Violations of instrument validity in an MR context often concern horizontal pleiotropy, that is, when
genetic instruments influence the outcome through independent pathways that are not mediated by the
exposure, thus breaking the exclusion restriction [27]. In our setting, the extent of this problem can be
quantified as
∑p
k=1 |γ(k)|2, and the rate restrictions from Bai and Ng [9] apply. When nY
/
p2 → 0, we
can permit a finite number of instruments to be invalid to the extent that
∑p
k=1 |γ(k)|2 is bounded. For
the case where nY is not small relative to p
2, all instruments are required to be valid, so that γ(k) = 0,
(k = 1, ..., p).
Assumptions 2.3(v), (vi) are similar to Assumption F of Bai ([7], p.144); the conditions are not restrictive
because the sums involve mean zero random variables.
For analysis of IV models under weak identification, many works [46, 47, 26] have adopted Staiger and Stock
[44]’s local-to-zero characterization of weak instruments. In particular, Assumption 2.2(iii) is replaced by
the following condition.
Assumption 2.4 (weak instrument asymptotics).
(i) for some positive constant κX , βX = κXn
− 12
Y ;
(ii) for γ
(k)
X = E[e(k)eX ] and some sequence 0 ≤ τp < 1 such that τp → 0 as p→∞,
|γ(k)X | =
O(n
− 12
Y ) for k = 1, ..., bτppc
o(n
− 12
Y ) for k = bτppc+ 1, ..., p.
Given Assumption 2.3(iii), as the sample size nY increases, Assumption 2.4(i) restricts the explanatory
power of the optimal unobservable instruments f , while Assumption 2.4(ii) is a restriction on the explana-
tory power of observable instruments z(k), (k = 1, ..., p). To explicitly relate the stated assumptions in
terms of a relevance condition, note that Cov(f, x) = E[ff ′]βX = O(n
− 12
Y ) under Assumption 2.4(i), and
Cov(z(k), x) = γ
(k)
X under Assumption 2.4(ii). The latter assumption states that as the number of observ-
able instruments increases, a shrinking proportion of them are permitted to have O(n
− 12
Y ) effects on the
exposure, while the remaining 1 − τp proportion have smaller o(n−
1
2
Y ) effects. This is justified by noting
that the observable instruments are not optimal, and thus are at best only as relevant as the optimal
instruments.
Assumption 2.4 is highly plausible in cis-MR investigations. Typically, in a gene region only a few genetic
instruments have a direct effect on the exposure. For the many remaining genetic instruments, any asso-
ciation with the exposure is largely driven through correlation with the truly causal instruments, and is
therefore of weaker magnitude.
3 Estimation and testing under strong and weak identification
3.1 Estimating the factor loadings
The factor loadings are estimated using the instrument covariance matrix calculated from the reference
sample. For a given number of factors r, let Λ¯ denote the p × r matrix with its columns given by the
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eigenvectors corresponding to the largest r eigenvalues of
∑nZ
i=1 ziz
′
i, multiplied by
√
p. Then, the estimated
(re-scaled) factor loadings are given by Λˆ = Λ¯
(
p−1Λ¯′Λ¯
)− 12 , so that p−1Λˆ′Λˆ = Ir.
For our analysis, the number of factors r is assumed known, for example, by inspection of the scree plot of
the instrument covariance matrix. When individual-level instrument data is available from the reference
sample, the number of factors can be consistently estimated using Bai and Ng’s [8] factor penalization
method under conditions weaker than Assumption 2.1.
When there is some correlation in the idiosyncratic terms of the factor model (2.2), Onatski [40] shows
that Bai and Ng’s method [8] tends to over-estimate the number of factors in finite samples, and develops a
consistent estimator based on directly identifying diverging eigenvalues from the sample covariance matrix.
For our summary data focus, Onatski’s method ([40], p. 1008) is operational using only the calculated
eigenvalues from the sample instrument covariance matrix.
3.2 Point estimation with LIML
As we do not have one-sample individual-level data on (x, y, z), we cannot directly minimize a sample
analogue of the orthogonality condition E[fu] = 0 describing θ0, as implied by Assumption 2.2(ii). Instead,
given our estimated factor loadings and summary association statistics, we minimize a normalized contrast
of the sample moment indicator
gˆn(θ) =
1
p
Λˆ′DˆY bˆY − θ1
p
Λˆ′DˆX bˆX
where DˆX and DˆY are p×p diagonal matrices with the k-th diagonal entries Dˆ(k)X and Dˆ(k)Y which estimate
D¨
(k)
X and D˙
(k)
Y , respectively (k = 1, ..., p), as discussed in Section 2.3.
Let Vˆn = Λˆ
′(∑nZ
i=1 ziz
′
i
)
Λˆ ⊗ n−1Z p−2, and for the exposure, let βˆX = Vˆ −1n Λˆ′DˆX bˆXp−1. For k = 1, ..., p,
compute ˆvar(k)(x) = Dˆ
(k)
X (nX σˆ
(k)2
mX + bˆ
(k)2
X ). Following Yang et al. [56], we take the median of ˆvar
(k)(x)
over k = 1, ..., p as the unconditional exposure variance estimate, ˆvar(x). Then, a consistent estimate of
the residual variance (see Lemma A.10 in the appendix) of the exposure given instrument factors is
σˆ2X = ˆvar(X)− βˆ′X VˆnβˆX .
The residual variance estimator for the outcome is defined analogously. Under our condition of homoskedas-
ticity of conditional exposure and outcome variances, an estimate of the optimal weighting matrix is given
by the inverse of
Ωˆn(θ) = Vˆn ⊗ (σˆ2Y + θ2cˆXY σˆ2X)
where cˆXY = (nY /nX) is the ratio of the assocation study sample sizes. Then, the factor-LIML (F-LIML)
estimator of the causal effect θ0 is given by
θˆ = arg min
θ
Qˆn(θ),
where the criterion to be minimized is Qˆn(θ) = gˆn(θ)
′Ωˆ−1n (θ)gˆn(θ).
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3.3 Identification-robust test statistics
MR analysis is primarily used to study the identification of a potential causal effect of an exposure on
outcome. Of central concern is therefore a test of the null hypothesis H0 : θ = θ0, versus the general
alternative H1 : θ 6= θ0. For this purpose, we adapt identification-robust AR, LM, and CLR test statistics
for our summary statistics setting with many correlated instruments.
We follow previous works [34, 26, 3] by constructing these test statistics as a function of two mutually
asymptotically independent statistics (S˜, T˜ ), with S˜ representing an exogeneity condition of the estimated
instruments, and T˜ incorporating information on the strength of identification.
Let Gˆn = −p−1Λˆ′DˆX bˆX , ∆ˆG(θ) = Vˆn ⊗ θcˆXY σˆ2X , and ∆ˆGG = Vˆn ⊗ cˆXY σˆ2X . Calculate the normalized
vectors S˜ = Ωˆn(θ0)
−1√nY gˆn(θ0) and T˜ = (∆ˆGG − ∆ˆG(θ0)′Ωˆn(θ0)−1∆ˆG(θ0))− 12√nY G˜n. Then, for Q˜S =
S˜′S˜, Q˜ST = S˜′T˜ , and Q˜T = T˜ ′T˜ , the AR, LM, and CLR test statistics with factor instruments and
summary statistics are given by
ARn = Q˜S
LMn = Q˜2ST
/
Q˜T
CLRn =
(
Q˜S − Q˜T +
√
(Q˜S + Q˜T )2 − 4(Q˜SQ˜T − Q˜2ST )
)/
2.
Under our assumptions and H0, ARn and LMn unconditionally converge to chi-squared distributed ran-
dom variables with degrees of freedom r and 1, respectively. Therefore, asymptotic α-level factor AR
(F-AR) and LM (F-LM) tests check whether the computed test statistics are greater than the (1− α)-th
quantile of the appropriate chi-squared distributions.
It is shown in the appendix that T˜ converges in distribution to a normal random variable ZT = N(G?, Ir),
where G? = −H?−1ΣΛE[fx], H? is a rotation matrix, and ΣΛ is the limit of p−1Λ′Λ as p→∞. Following
Moreira [34], CLRn is conditionally pivotal given ZT , and its conditional limiting distribution can then
be used to derive critical values by simulation; see, for example, [5], pp.743-5. Alternatively, Andrews
et al. [4] provide the analytical form of the asymptotic conditional p-value of the CLR test under weak
instrument asymptotics, which is stated here for completeness. Under H0, the conditional probability that
CLRn exceeds m given Q˜T = q˜T is asymptotically equivalent to
p?(m; q˜T ) = 1− 2K
∫ 1
0
P
(
χ2(r) < (1 +m−1q˜T s2)−1q˜T +m
)
(1− s2)(r−3)/2ds,
where χ2(r) is a chi-squared random variable with r degrees of freedom, K = Γ(0.5r)
/
(pi
1
2 Γ(0.5(r − 1)),
pi is the mathematical constant ‘pi’, and Γ(.) is the gamma function. An asymptotic α-level factor CLR
(F-CLR) test rejects H0 if p?(CLRn, q˜T ) < α.
The tests can be inverted to obtain confidence sets for θ0. A (1−α)-percent confidence set is given by the
set of values θ0 for which the null hypothesis H0 is not rejected by an asymptotic α-level test.
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4 Asymptotic results
This section presents asymptotic results that relate to the estimators and tests proposed in Section 3.
Proofs of the following results are given in the appendix.
Proposition 4.1 (F-LIML estimator). Under Assumptions 2.1-2.3, (i) θˆ
P→ θ0; (ii) θˆ is asymptotically
normal, such that √
nY (θˆ − θ0) D→ N(0,Σ)
where Σ = (G′0Ω
−1
0 G0)
−1, Ω0 = E[ff ′] ⊗ (σ2Y + θ20cXY σ2X), and G0 = −E[fx]; (iii) Σˆ P→ Σ, where
Σˆ = (Gˆ′nΩˆn(θˆ)
−1Gˆn)−1 and Gˆn = −p−1Λˆ′DˆX bˆX .
Inoue and Solon [30] discuss the asymptotic inefficiency of two-sample IV estimators [6], and instead
propose an estimator based on a two-stage least squares (TSLS) approach which achieves asymptotic
efficiency in a class of limited information estimators. The corresponding asymptotic variance ([30], p.559)
is equivalent to Σ with the unobservable factors f used as the optimal instruments.
The following results state the asymptotic distributions of the test statistics introduced in Section 3.3
under the null hypothesis H0 : θ = θ0, and weak instrument asymptotics.
Proposition 4.2 (Test statistics under weak identification). Under Assumptions 2.1, 2.2(i),(ii),
2.3, and 2.4, under H0, and conditional on ZT , (i) ARn D→ χ2(r); (ii) LMn D→ χ2(1); (iii) CLRn D→(
χ2(1)+χ2(r−1)−Z ′TZT +
[
(χ2(1)+χ2(r−1)−Z ′TZT )2 +4χ2(1)Z ′TZT
] 1
2
)/
2, where χ2(1) and χ2(r−1)
denote independent chi-square random variables.
Thus, the proposed test statistics have the same limiting distribution as the infeasible AR, LM, and CLR
tests with individual-level data and optimal instruments f , cf. Smith [42], pp.244-7.
5 Simulation study
The purpose of this simulation study is to analyze the performance of the proposed estimators and tests over
realistic scenarios. Firstly, finite-sample accuracy of the F-LIML estimator and standard error estimates
will determine correct inferences in MR analyses when factors are strong instruments. As a result, we
check whether the standardized estimate is approximately standard normal over repeated experiments,
as suggested by Proposition 4.1. The performance of the F-LIML estimator is also compared against the
IVWPC estimator proposed in [18], which is also designed to deal with many correlated genetic instruments.
Second, for any recommendation of use, it is important to know under what conditions bounds obtained by
inverting identification-robust tests are sufficiently tight to be informative for cis-MR analysis. We examine
this by comparing the coverage and width of confidence intervals computed for the F-LIML estimator with
intervals obtained by inverting the F-CLR test.
Finally, since MR tests are concerned with identifying the existence of an unconfounded effect of exposure
on disease, we analyze the size and power properties of a test of parameter significance H0 : θ = 0 against
the general alternative H1 : θ 6= 0. A higher value of the residual exposure variance σ2X necessarily implies
decreased instrument strength. Therefore, in order to assess robustness to weak instruments, all results
are displayed as a function of σX .
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5.1 Design
In order to ensure our experiments study realistic instrument correlation structures, we use genotype data
from a gene region of potential interest for MR analyses of antihypertensive drugs. Genotype data on
p = 261 genetic variants, forming the instrumental variables, in the 12SLCA3 gene region were sampled
without replacement from participants in the UK Biobank study. For each experiment, data on nZ =
10, 000 individuals was sampled to construct an instrument correlation matrix. From the remaining UK
Biobank sample, for each experiment, nX and nY -sized samples were drawn to provide data {z˙i}nYi=1 and
{z¨i}nXi=1 with no overlap between the two samples, and were used to construct summary statistics on genetic
associations. For each of the three samples, instrument sample variances were also calculated in order to
provide enough information to obtain the covariance matrix of instruments, and to estimate the required
quantities D¨
(k)
X for the exposure, and D˙
(k)
Y for the outcome (k = 1, ..., p).
Data on the outcome and exposure was generated as
y = θ0β
′
X z˙
? + eY
x = β′X z¨
? + eX ,
where eX and eY are error terms. A fixed vector Z
? of 8 instruments, from the full 261 instruments,
were selected to have a direct effect on X and Y , such that they have varied correlation between them.
As before, for instruments Z? taking values z?, the notation z˙? and z¨? indicates that the instrument-
exposure and instrument-outcome association data were drawn from independent samples {z˙i}nYi=1 and
{z¨i}nXi=1, respectively. The causal effect was θ0 = 0.25, and βX = 0.2. The error terms were generated as
eX ∼ N(0, σ2X) and eY ∼ N(0, σ2Y ), for σX ∈ {3, 4, 5, 6} and σY = σX . This corresponds to the proportion
of exposure variance explained to (approximately) take values {0.33, 0.22, 0.15, 0.11}, and the proportion
of outcome variance explained to vary from 0.01 to 0.03 as σX decreases. Finally, effect sizes and standard
errors from univariate outcome on instruments, and exposure on instruments, regressions were computed
to provide the required summary data.
Figure 5.1. Genetic instrument correlation matrix from 12SLCA3 gene region (left) and a corresponding scree plot (right).
Figure 5.1 presents the correlation structure for the set of instruments considered for our simulations,
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with the scree plot showing a significant gap between the 6-th and 7-th eigenvalues, as required in our
assumptions. A simulation exercise revealed that the number of factors estimated with Bai and Ng’s [8]
method, under large random sampling from UK Biobank data, remains constant at rˆ = 6. Thus, r = 6
was set as the number of factors to be estimated for the estimators and tests considered here.
5.2 Accuracy of F-LIML estimators and standard errors
The performance of the F-LIML estimator is illustrated in Figure 5.2, and serves to verify the accuracy of
our asymptotic approximations for the distribution of the causal effect θ0. The histogram of the F-LIML
estimator more closely matches the standard normal density as compared with the IVWPC estimator, but
its performance under weak instruments may be of concern. For strong instrument cases (for example,
when σX = 3 and σX = 4), standard errors and confidence intervals for θ0 based on our asymptotic results
should be accurate. In general, the performance of both F-LIML and IVWPC estimators is competitive
when both sample sizes nY and nX are large, however for the case nX = 500 and nY = 5000, the IVWPC
estimator is biased toward zero and has little coverage around the true value. In contrast, F-LIML is
considerably less biased.
Figure 5.2. Histograms of standardized F-LIML (yellow) and IVWPC (blue) estimates of θ0. Estimator bias is calculated as
the mean estimate of θ0 taken over 2000 simulations. The black curve displays the standard normal density.
The number of principal components used for IVWPC estimation was also set at r = 6, and explained
around 99 percent of genetic variation in the instruments. Therefore, the number of principal components
selected does not seem to be the cause of the relative good performance of F-LIML over IVWPC. The
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gains could be due to the well-documented robustness of LIML over TSLS [21, 39, 17, 22], and efficiency
of one-step generalized method of moments estimators over TSLS estimators [37].
When nX = 500 and σX = 6, we are in what could be described as a weak instruments scenario under
Staiger and Stock’s [44] rule of thumb. In particular, a regression of x on z? yields an F-statistic of
approximately 8.75. It is natural to then ask whether inverting the weak instrument robust tests described
in Section 3.3 provide more reliable insight on the value of θ0.
Given that the CLR test is widely regarded as a more powerful test than LM and AR in practice [3, 2, 53],
we focus our attention on comparing 95 percent asymptotic confidence intervals of F-LIML with the
corresponding intervals for F-CLR. The F-LIML confidence intervals are computed using consistently-
estimated standard errors using our asymptotic results from Proposition 4.1.
σX = 3 σX = 4 σX = 5 σX = 6
nX nY f-liml f-clr f-liml f-clr f-liml f-clr f-liml f-clr
500 500
Coverage 0.930 0.954 0.894 0.955 0.860 0.962 0.837 0.972
Width 0.692 1.052 0.957 4.091 1.409 10.404 1.829 15.782
500 5000
Coverage 0.919 0.941 0.897 0.952 0.868 0.969 0.829 0.966
Width 0.273 0.394 0.369 1.819 0.553 6.743 0.699 12.477
5000 5000
Coverage 0.948 0.951 0.955 0.959 0.938 0.944 0.938 0.946
Width 0.223 0.218 0.297 0.299 0.370 0.383 0.445 0.477
Table 5.1. 95 percent F-LIML and F-CLR asymptotic confidence intervals, averaged over 2000 simulations.
Table 5.1 displays excellent coverage of F-CLR confidence intervals under all sample sizes and instrument
strengths considered. In contrast, there is under-coverage with F-LIML intervals when nX = 500 at all
levels of σX , with the problem worsening as σX increases. However, in general, the width of the F-CLR
intervals when nX = 500 are likely to be too wide to be of practical interest. Interestingly, when nX
is large, the F-CLR confidence intervals are just as tight as F-LIML intervals. Despite the drawback of
not having a point estimate, this demonstrates a clear value of using F-CLR test inversion for inference
involving large nX sample sizes, as may be likely when working with GWAS data.
5.3 Type I error and power of MR tests under weak instruments
For analysis of identification-robust tests, some of the model parameters described in Section 5.1 are slightly
altered. In keeping with an MR interest of identifying a significant causal effect, type I error rates with the
true value set at θ0 = 0 are examined, and power analysis considers rejection rates as the true value moves
away from 0. The vector of weak instruments effects, βX , had each element equal to 1
/√
nX . Values for
the residual exposure variance σX were chosen to maintain a specific level of the F-statistic; this is because
the latter measure is more readily interpretable for summarizing the extent of a weak instrument problem.
Unbalanced sample sizes are common in some cis-MR applications, where gene or protein expression
(instrument-exposure) associations are typically derived from a much smaller dataset, as in our Section 6
example. Since this is likely to present a further challenge compared with MR studies using very large nX
and nY samples from GWASs, we narrow our power analysis to the case where nX = 500 and nY = 5000.
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Figure 5.3. Type I error rates: rejection frequencies of the IVWPC, F-LIML, F-LM, F-AR, and F-CLR tests when θ0 = 0.
The black (dashed) line indicates where estimated size equals nominal size.
The IVWPC and F-LIML tests are based on simple t-statistics, comparing the normalized causal parameter
estimates with its limiting N(0, 1) distribution underH0, as suggested by Proposition 4.1. Figure 5.3 shows
that the F-LIML test fails to control type I error under weak instruments, and is over-sized in finite samples
even when instruments are strong. In contrast, the IVWPC test controls type I error, along with all the
identification-robust tests.
The concentration parameter is another commonly used measure of the strength of instruments, and
is a simple function of the F-statistic. In our case, the concentration parameter is given by λn =
nXβ
′
XE[z?z?′]βX
/
σ2X . The x-axis in Figure 5.4 is scaled by
√
λn to allow easier comparison of panels,
since instrument strength, as well causal effect magnitude, dictates power; cf. [4].
Due to its poor type I error control, F-LIML was not considered for the power analysis. Since the remaining
tests appear to have very similar size properties, a valid power analysis can simply compare rejection
frequencies as the data generating model is altered such that the true value θ0 deviates from 0.
The F-AR test appears to have difficulty discriminating against subtle deviations away from the null when
instruments are strong, which is similar to finite-sample evidence for the AR test found elsewhere, see, for
example, [34]. Poor power properties of AR tests are also linked to a large dimension of the instrument
vector [2, 5], which may not be an issue given our first-stage dimension-reduction of the set of genetic
instruments. The F-AR test is very competitive with very weak instruments, but is relatively under-
powered under the strong instrument case (F-statistic of 32). The opposite features can be seen for the
F-LM test, which is significantly under-powered under weak instruments.
Even in the strong instrument design discussed in Section 5.2, for nX = 500 cases, the IVWPC estimates
were systematically biased towards zero when residual exposure variance was increased. This pattern is
consistent with the IVWPC type I error control shown in Figure 5.3 under the null hypothesis of a zero
effect. The low power of the IVWPC test in Figure 5.4 further suggests that the IVWPC approach is
unlikely to detect, or accurately estimate, a significant effect under weak instruments.
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Figure 5.4. Power curves: rejection frequencies of the IVWPC, F-LM, F-AR, and F-CLR tests of parameter significance.
The black (dashed) line displays the 0.05 nominal size of the tests.
Figures 5.2 and 5.3 also suggest that F-LIML may offer improved point estimation and inference when
instruments are very strong. Therefore, in some GWAS applications with high sample sizes and previously
evidenced strong genetic association with the exposure, F-LIML may be a viable option for obtaining point
estimates. Unfortunately, type I errors under F-LIML seem to be very inflated under weak instruments;
the use of its associated t-test is more likely to falsely conclude in an existence of a causal effect when there
is not. It is possible to construct limiting chi-squared test statistics [38] using F-LIML estimates, but they
will also not provide valid tests under weak instruments.
Over all sample sizes and instrument strengths considered, F-CLR appears to be the most powerful test.
Under strong enough instruments, our results suggest test inversion provides a tight bound of the causal
effect, comparable to what would be obtained using confidence intervals of point estimators. The perfor-
mance of F-LM and F-AR tests are sensitive to instrument strength, whereas F-CLR offers reliable power
and type I error control. Thus, our simulation study concludes the F-CLR test may be considered for use
in practice.
6 Empirical example: IL6R signaling and glycated hemoglobin
Interleukin 6 Receptor (IL6R), encoded by the gene IL6R, is a protein involved in inflammation. Circulating
soluble IL6R levels are measurable using proteomic assays and inversely relate to IL6R signaling, which
has been implicated in increasing circulating glucose levels and diabetes risk [33]. Glycated hemoglobin
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(HbA1c) levels can be used to estimate blood glucose levels over a three month period, and thus serves as
a measure of glycemic control [54].
In this example, we investigate whether genetically predicted circulating IL6R levels are inversely associated
with increased HbA1c levels. In relation to our IV model, the exposure X is circulating IL6R level, outcome
Y the HbA1C level, and instruments Z are genetic variants in close proximity to the IL6R locus.
Summary genetic association estimates for circulating IL6R levels were taken from a GWAS of 3,301
individuals of European ancestry in the INTERVAL study and were measured in standard deviation units
[49]. Summary genetic association estimates for HbA1c were taken from a GWAS of 344,182 individuals
of White British ancestry in the UK Biobank and were measured in mmol/mol units [35]. UK Biobank
data was also used to calculate the sample instrument covariance matrix.
Figure 6.1. Proportionality of genetic association effect sizes; bˆY plotted against bˆX (left), and βˆY plotted against βˆX with
r = 12.
To source genetic instruments, a region including 200kb either side of the IL6R locus was considered
(chromosome 1, position 154,177,669–154,641,926 on GRCh37/hg19), as determined through GeneCards
[45]. Within this region, there were p = 1413 genetic variants that were present in both samples. The
genetic instruments exhibited structured correlation, which is typical of genetic variants from within the
same gene region; the first 9 and 19 principal components explained approximately 95 and 99 percent of
genetic variation, respectively.
The left panel of Figure 6.1 suggests an inverse relationship of circulating IL6R and HbA1C levels, although
with some heterogeneity in the proportionality pattern. Given the large number of genetic instruments
considered, such overdisperation is typically expected and is unlikely to invalidate an MR analysis [15].
Furthermore, by Bai and Ng [9], some protection against invalid instruments is provided by factor-estimated
instruments, theoretically, if the square root of the association study sample sizes are small relative to the
number of instruments. In this example,
√
nY
/
p is approximately equal to 0.172, and therefore our analysis
is arguably robust to some genetic variants being invalid instruments.
Table 6.1 presents estimates of the effect of circulating IL6R levels on HbA1C levels, calculated by F-CLR,
F-LIML, and IVWPC methods. We chose r=12 factors since there was a noticeable drop between the 12th
and 13th eigenvalues in the scree plot of the instrument covariance matrix. For a 95 percent confidence set,
the F-CLR method estimates that 1 standard deviation increase in circulating IL6R levels is associated
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with a θ0 ∈ [−0.0928,−0.0378] mmol/mol change in HbA1C levels. For a reasonable number of factors
selected, the F-CLR set estimates comfortably contain the F-LIML and IVWPC point estimates, which
are almost identical for r = 12; θˆ = −0.0653.
r 4 12 36
method f-clr f-liml ivwpc f-clr f-liml ivwpc f-clr f-liml ivwpc
estimate NA - 0.0811
(0.0170)
- 0.0629
(0.0141)
NA - 0.0653
(0.0140)
- 0.0652
(0.0139)
NA - 0.0658
(0.0137)
- 0.0645
(0.0125)
95% C.I. −0.0479
−0.1146
−0.0478
−0.1144
−0.0352
−0.0906
−0.0378
−0.0928
−0.0378
−0.0927
−0.0379
−0.0925
−0.0388
−0.0928
−0.0390
−0.0925
−0.0399
−0.0890
Table 6.1. Estimates, standard errors, and 95 percent confidence intervals, of a 1 standard deviation increase in circulating
IL6R levels on HbA1C levels (mmol/mol). Standard errors are in brackets.
Under a simpler univariate approach, Swerdlow et al. [50] found evidence that the genetic variant rs7529229
in the IL6R gene was associated with reduced risk of type 2 risk of diabetes. In the INTERVAL study
that we analyze here, rs4129567, which is correlated with rs7529229 at R2 = 0.98, represented a slightly
stronger instrument for IL6R; see Figure 6.2. A Wald ratio estimate with a single genetic instrument
rs4129567 was estimated as θˆW = −0.073, with 95 percent confidence interval θ0 ∈ [−0.1005,−0.0458],
and is therefore similar to results reported in Table 6.1. We conclude that IL6R signaling is a causal
determinant of HbA1c levels.
The very strong association of several genetic variants with circulating IL6R levels, as shown in Figure
6.2, along with structured correlation between instruments, means that it is unlikely that we are in a weak
instruments scenario for this particular study. This is also consistent with the close results obtained from
the several methods considered above. However, these results offer empirical evidence that test inversion
of the F-CLR method is a viable tool that can provide tight set estimates of the causal effect.
Figure 6.2. P-values from GWAS marginal regressions. The genetic variant rs4129267 had the lowest p-value, and was in
approximately 98 percent correlation with the genetic variant rs7529229, which has previously been suggested to be
associated with reduced risk of type 2 diabetes [50].
In this example we found a selection of r = 12 factors to be appropriate. However, when analyzing large
numbers of variants in dense genotype data, it will not always be so clear that such a modest number of
factors is sufficient. Considering the two approaches that offer a point estimate of the causal effect, in
contrast to LIML, the TSLS estimator is asymptotically biased under many instrument asymptotics [36].
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If a large number of factor-based instruments are included, we may expect the IVWPC estimator, which
is a meta-analysis generalization of TSLS with principal components, to be inconsistent when a large
number of factors are selected. In this study, when r = 180 factors are selected, the 95 percent F-CLR
bound estimate, θ0 ∈ [−0.0919,−0.0472], and the F-LIML estimate, θˆ = −0.0696, were not significantly
changed, but the IVWPC estimate was reduced to θˆIVWPC = −0.0507. Given that the identification-
robust statistics considered in this paper are designed to handle estimated instruments that have weak
signals with the exposure, we would expect F-CLR to be particularly robust to the inclusion of irrelevant
factors.
7 Conclusion
The theoretical developments in this paper have been targeted towards addressing practical issues faced by
increasingly exploratory applications of candidate gene MR. The approximate factor model which assumes
there is a finite number of factors for an increasingly large number of genetic instruments is theoretically
justified for cis-MR application. The method considered in this paper efficiently uses the information of
systematic genetic variation in the gene region in order to estimate optimal instruments. This approach is
likely to be particularly useful for situations in which there may be multiple and/or weak genetic effects
on the exposure, since selection of instruments based on their strength of association with the exposure
would lead to biased estimation and size-distorted tests.
Since the linear IV model is ubiquitous in empirical research, our results could also have interesting
implications, beyond MR, for IV analysis using high-dimensional summary statistics. A simulation study,
and an empirical example, suggest that test inversion of the F-CLR test statistic may offer tight bounds
for the causal effect under strong identification. The F-CLR test also controls type I error and displays
favourable finite-sample power properties under weak identification. As such, F-CLR inference is a credible
option regardless of instrument strength.
A Proof of theoretical results
A.1 Notation
The following abbreviations are used: CS: the Cauchy-Schwarz inequality; S: Slutsky’s theorem; T: the
triangle inequality; M: Markov’s inequality; WLLN: the weak law of large numbers; CLT: the Lindeberg-
Le´vy central limit theorem; p.d.: positive definite; w.p.a.1: ‘with probability approaching one’; LHS:
‘left-hand side’; RHS: ‘right-hand side’; ∇θ is the first derivative with respect to θ; ∇θθ is the second
derivative with respect to θ; tr(A) is the trace of a matrix A; Ir is the r × r identity matrix. For the
further notation below, H is a matrix introduced in Lemma A.1.
The following notation concerns the moment function:
gˆn(θ) =
1
p Λˆ
′DˆY bˆY − θ 1p Λˆ′DˆX bˆX
gn(θ) = H
−1( 1
pΛ
′Λ
)(
1
nY
∑nY
i=1 f˙iyi − θ 1nX
∑nX
i=1 f¨ixi
)
.
The following notation concerns the first derivative of the moment function:
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Gˆn = − 1p Λˆ′DˆX bˆX
Gn = −H−1
(
1
pΛ
′Λ
)
1
nX
∑nX
i=1 f¨ixi.
The following notation concerns the variance of the moment function:
Vˆn =
1
nZ
∑nZ
i=1
(
1
p Λˆ
′zi
)(
1
p Λˆ
′zi
)′
Vn = H
−1
(
1
pΛ
′Λ
)(
1
nZ
∑nZ
i=1 fif
′
i
)(
1
pΛ
′Λ
)
H−1′.
The following notation concerns the F-LIML objective function:
Aˆn(θ) = gˆn(θ)
′Vˆ −1n gˆn(θ)
An(θ) = gn(θ)
′V −1n gn(θ)
Bn(θ) = σˆ
2
Y + θ
2cˆXY σˆ
2
X
Qˆn(θ) = Aˆn(θ)/Bn(θ).
A.2 Preparatory lemmata
Let F = (f1, ..., fnZ )
′ be the nZ × r matrix of true factors, and Fˆ = (fˆ1, ..., fˆnZ )′ be the estimated matrix
of factors, where fˆi =
1
p Λˆ
′zi, (i = 1, ..., nZ). For comparability to Bai [7], instead of normalizing the factor
loadings such that 1p Λˆ
′Λˆ = Ir, we work with the normalization 1nZ
∑nZ
i=1 fˆifˆ
′
i =
1
p2 Λˆ
′( 1
nZ
∑nZ
i=1 ziz
′
i
)
Λˆ = Ir,
cf. Bai and Ng [8], p. 198.
Lemma A.1. Let H = ( 1pΛ
′Λ)( 1nZ F
′Fˆ )D−1np , where Dnp is an r × r diagonal matrix of the first r largest
eigenvalues of 1nZp
∑nZ
i=1 ziz
′
i in decreasing order. Under Assumption 2.1, (i) ||H|| = OP (1); (ii) ||H−1|| =
OP (1).
Proof. By Lemma A.3 of Bai ([7], p.161; also see p.158), Dnp
P→ D, a diagonal matrix with the eigenvalues of
ΣΛE[ff ′]. Hence, w.p.a.1, D−1np exists by Assumptions 2.1(ii),(iii) since ΣΛ and E[ff ′] are p.d., and ||D−1np || =
OP (1). By construction,
1
nZ
∑nZ
i=1 fˆifˆ
′
i = Ir. Thus, || 1nZ
∑nZ
i=1 fˆifˆ
′
i || = O(1). By Assumption 2.1(ii), CS and M,
|| 1
nZ
∑nZ
i=1 fif
′
i || ≤ 1nZ
∑nZ
i=1 ||fi||2 = OP (1).
Similarly, by Assumption 2.1(iii), ||λ(k)|| ≤ C <∞ (k = 1, ..., p), so that by CS, || 1
p
Λ′Λ|| ≤ 1
p
∑p
k=1 ||λ(k)||2 = O(1).
Also, by CS, ||H|| ≤ || 1
p
Λ′Λ|| · || 1
nZ
∑nZ
i=1 fif
′
i ||
1
2 · || 1
nZ
∑nZ
i=1 fˆifˆ
′
i ||
1
2 · ||D−1np ||, so that ||H|| = OP (1). H is invertible
(see Bai [7], p.145). Therefore by Part (i), ||H−1|| = OP (1). 
Lemma A.2. Under Assumption 2.1, for any k = 1, ..., p, ||λˆ(k)−H−1λ(k)|| = OP (n−
1
2
Z )+OP (min(nZ , p)
−1).
Proof. By Bai ([7], p.165), for any k = 1, ..., p, we have
λˆ(k) −H−1λ(k) = H ′ 1
nZ
nZ∑
i=1
fie
(k)
i +
1
nZ
nZ∑
i=1
fˆi(fi −H ′−1fˆi)′λ(k) + 1
nZ
nZ∑
i=1
(fˆi −H ′fi)e(k)i . (A.1)
Hence, by CS,
‖λˆ(k) −H−1λ(k)‖ ≤ n−
1
2
Z · ‖H‖ ·
∥∥∥ 1√
nZ
nZ∑
i=1
fie
(k)
i
∥∥∥+ ∥∥∥ 1
nZ
nZ∑
i=1
fˆi(fi − fˆiH)′
∥∥∥ · ‖λ(k)‖+ ∥∥∥ 1
nZ
nZ∑
i=1
(fˆi −Hfi)e(k)i
∥∥∥,
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where the first term on the RHS is OP (n
− 1
2
Z ) by Lemma A.1(i), Assumption 2.1(vii), and M. The second term on
the RHS is OP (min(nZ , p)
−1) by Lemma B.3 of Bai ([7], p.165), and Assumption 2.1(iii). The third term on the
RHS is OP (min(nZ , p)
−1) by Lemma B.1 of Bai ([7], p.163). 
Lemma A.3. Under Assumptions 2.1-2.3, ||gˆn(θ)− gn(θ)|| = oP (1).
Proof. Noting that 1
p
Λ′z = ( 1
p
Λ′Λ)f + 1
p
Λ′e, we can write
gˆn(θ) = gn(θ) +H
−1 1
p
p∑
k=1
λ(k)
( 1
nY
ny∑
i=1
e˙
(k)
i yi − θ
1
nX
nX∑
i=1
e¨
(k)
i xi
)
+
1
p
p∑
k=1
(λˆ(k) −H−1λ(k))
( 1
nY
nY∑
i=1
z˙
(k)
i yi − θ
1
nX
nX∑
i=1
z¨
(k)
i xi
)
+H−1
1
p
p∑
k=1
λ(k)
[
(Dˆ
(k)
Y − D˙(k)Y )bˆ(k)Y − θ(Dˆ(k)X − D¨(k)X )bˆ(k)X
]
+
1
p
p∑
K=1
(λˆ(k) −H−1λ(k))
[
(Dˆ
(k)
Y − D˙(k)Y )bˆ(k)Y − θ(Dˆ(k)X − D¨(k)X )bˆ(k)X
]
:= gn(θ) +R1n +R2n +R3n +R4n. (A.2)
Then, by CS,
‖R1n‖ ≤ p− 12 · ‖H−1‖ ·
( 1
nY
nY∑
i=1
∥∥∥ 1√
p
p∑
k=1
λ(k)e˙
(k)
i
∥∥∥2) 12 ( 1
nY
nY∑
i=1
|yi|2
) 1
2
+p−
1
2 · |θ| · ‖H−1‖ ·
( 1
nX
nX∑
i=1
∥∥∥ 1√
p
p∑
k=1
λ(k)e¨
(k)
i
∥∥∥2) 12 ( 1
nX
nX∑
i=1
|xi|2
) 1
2
= OP (p
− 1
2 ), (A.3)
where the equality follows by Lemma A.1(ii), Assumptions 2.1(vii), 2.2(i), and M.
By CS,
‖R2n‖ ≤
(1
p
p∑
k=1
‖λˆ(k) −H−1λ(k)‖2
) 1
2
(1
p
p∑
k=1
( 1
nY
nY∑
i=1
|z˙(k)i | · |yi|
)2) 1
2
|θ| ·
(1
p
p∑
k=1
‖λˆ(k) −H−1λ(k)‖2
) 1
2
(1
p
p∑
k=1
( 1
nX
nX∑
i=1
|z¨(k)i | · |xi|
)2) 1
2
= OP (min(nZ , p)
−1), (A.4)
by Lemma A.2, Assumption 2.2(i), and M, after noting, for example, that E[|z(k)||y|]2 ≤ E[|z(k)|2]E[|y|2] ≤ CE[|y|2].
By repeated use of CS,
‖R3n‖ ≤ ‖H−1‖ ·
(1
p
p∑
k=1
‖λ(k)‖4
) 1
4
[(1
p
p∑
k=1
|Dˆ(k)Y − D˙(k)Y |4
) 1
4
(1
p
p∑
k=1
|bˆ(k)Y |2
) 1
2
+|θ| ·
(1
p
p∑
k=1
|Dˆ(k)X − D¨(k)X |4
) 1
4
(1
p
p∑
k=1
|bˆ(k)X |2
) 1
2
]
= oP (n
− 1
2
Y ) + oP (n
− 1
2
X ), (A.5)
by Lemma A.1(ii), Assumptions 2.1(iii), 2.2(i), 2.3(ii), and M, noting that, for example, |b(k)Y |2 ≤
(
1
nY
∑nY
i=1 z˙
(k)2
i
)−1
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·( 1
nY
∑nY
i=1 |z˙(k)i ||yi|
)2
= OP (1), since
1
nY
∑nY
i=1 z˙
(k)2
i > 0 for all k = 1, ..., p, and E[|z(k)||y|] ≤ CE[|y|2]
1
2 , by the
same arguments used to bound ‖R2n‖.
Also,
‖R4n‖ ≤
(
OP (min(nZ , p)
−1) +OP (n
− 1
2
Z )
)(
oP (n
− 1
2
Y ) + oP (n
− 1
2
X )
)
, (A.6)
by identical arguments for bounding ‖R3n‖, using Lemma A.2.
Thus, by (A.2)− (A.6), CS, and Assumption 2.3(iii), and p→∞, ‖gˆn(θ)− gn(θ)‖ = oP (1). 
Lemma A.4. Under Assumptions 2.1-2.3, ||Gˆn −Gn|| = oP (1).
Proof. Noting that 1
p
Λ′z = ( 1
p
Λ′Λ)f + 1
p
Λ′e, we can write
Gˆn −Gn = θH−1 1
p
p∑
k=1
λ(k)
1
nX
nX∑
i=1
e¨
(k)
i xi + θ
1
p
p∑
k=1
(λˆ(k) −H−1λ(k)) 1
nX
nX∑
i=1
z¨
(k)
i xi
+θH−1
1
p
p∑
k=1
λ(k)(Dˆ
(k)
X − D¨(k)X )bˆ(k)X + θ
1
p
p∑
K=1
(λˆ(k) −H−1λ(k))(Dˆ(k)X − D¨(k)X )bˆ(k)X ,
where the norm of each of the RHS terms is oP (1) by identical arguments used in Proof of Lemma A.3. The result
then follows by CS. 
Lemma A.5. Under Assumptions 2.1-2.3, ||Vˆn − Vn|| = oP (1).
Proof. Since 1
p
Λ′z = ( 1
p
Λ′Λ)f + 1
p
Λ′e, we can write
H−1
1
p2
Λ′
( 1
nZ
nZ∑
i=1
ziz
′
i
)
ΛH−1′ = Vn +H
−1
(1
p
Λ′Λ
)( 1
nZp
p∑
k=1
nZ∑
i=1
λ(k)e
(k)
i f
′
i
)′
H−1′
+H−1
( 1
nZp
p∑
k=1
nZ∑
i=1
λ(k)e
(k)
i f
′
i
)(1
p
Λ′Λ
)
H−1′
+H−1
1
nZ
nZ∑
i=1
(1
p
p∑
k=1
λ(k)e
(k)
i
)(1
p
p∑
k=1
λ(k)e
(k)
i
)′
H−1′.
Thus, since
Vˆn −H−1 1
p2
Λ′
( 1
nZ
nZ∑
i=1
ziz
′
i
)
ΛH−1′ =
1
p2
(Λˆ− ΛH−1′)′
( 1
nZ
nZ∑
i=1
ziz
′
i
)
(Λˆ− ΛH−1′)
+
1
p2
(Λˆ− ΛH−1′)′
( 1
nZ
nZ∑
i=1
ziz
′
i
)
ΛH−1′
+H−1
1
p2
Λ′
( 1
nZ
nZ∑
i=1
ziz
′
i
)
(Λˆ− ΛH−1′),
by repeated use of CS, we have
‖Vˆn − Vn‖ ≤ 2‖H−1‖2 ·
∥∥∥1
p
Λ′Λ
∥∥∥ · ∥∥∥ 1
nZp
p∑
k=1
nZ∑
i=1
λ(k)e
(k)
i f
′
i
∥∥∥+ p−1‖H−1‖2 · 1
nZ
nZ∑
i=1
∥∥∥ 1√
p
p∑
k=1
λ(k)e
(k)
i
∥∥∥2
+2‖H−1‖ ·
(1
p
p∑
k=1
‖λˆ(k) −H−1λ(k)‖2
) 1
2 ·
(1
p
p∑
k=1
‖λ(k)‖2
) 1
2 ·
( 1
nZp
nZ∑
i=1
p∑
k=1
|z(k)i |2
)
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+
(1
p
p∑
k=1
‖λˆ(k) −H−1λ(k)‖2
)
·
( 1
nZp
nZ∑
i=1
p∑
k=1
|z(k)i |2
)
:= R5n +R6n +R7n +R8n.
For R1n, by CS,
∥∥∥ 1
nZp
p∑
k=1
nZ∑
i=1
λ(k)e
(k)
i f
′
i
∥∥∥ ≤ n− 12Z ·max
k
‖λ(k)‖ · 1
p
p∑
k=1
∥∥∥ 1√
nZ
nZ∑
i=1
fie
(k)
i
∥∥∥
= OP (n
− 1
2
Z ),
by Assumptions 2.1(iii), (vii) and M. Hence, by Lemma A.1(ii), Assumption 2.1(iii) and M, R5n = OP (n−
1
2
Z ).
By Lemma A.1(ii), Assumption 2.1(vii), and M, R6n = OP (p−1). R7n = OP (n−
1
2
Z ) + OP (min(nZ , p)
−1) by
Lemmas A.1(ii), A.2, and Assumptions 2.1(iii), 2.2(i). Finally, by Lemma A.2 and Assumption 2.2(i), R8n =
OP (n
− 1
2
Z ) +OP (min(nZ , p)
−1).
Therefore, by CS, and Assumption 2.3(iii) and p→∞, ‖Vˆn − Vn‖ = oP (1). 
Lemma A.6. Under Assumptions 2.1-2.3, (i) ||gˆn(θ)|| = OP (1); (ii) ||gn(θ)|| = OP (1).
Proof. By CS,
||gˆn(θ)|| ≤ ||H−1|| ·
(1
p
p∑
k=1
||λ(k)||4
) 1
4 ·
(1
p
p∑
k=1
Dˆ
(k)4
Y
) 1
4 ·
(1
p
p∑
k=1
|bˆ(k)Y |2
) 1
2
+
(1
p
p∑
k=1
||λˆ(k) −H−1λ(k)||4
) 1
4 ·
(1
p
p∑
k=1
Dˆ
(k)4
Y
) 1
4 ·
(1
p
p∑
k=1
|bˆ(k)Y |2
) 1
2
+|θ| ·
[
||H−1|| ·
(1
p
p∑
k=1
||λ(k)||4
) 1
4 ·
(1
p
p∑
k=1
Dˆ
(k)4
X
) 1
4 ·
(1
p
p∑
k=1
|bˆ(k)X |2
) 1
2
+
(1
p
p∑
k=1
||λˆ(k) −H−1λ(k)||4
) 1
4 ·
(1
p
p∑
k=1
Dˆ
(k)4
X
) 1
4 ·
(1
p
p∑
k=1
|bˆ(k)X |2
) 1
2
]
:= R9n +R10n +R11n +R12n.
For all k = 1, ..., p, 1
nZ
∑nZ
i=1 |z(k)i |2 = OP (1), by Assumption 2.2(i), so that by CS, M, and Assumption 2.3(ii),
|Dˆ(k)Y | = Op(1). Also, |b(k)Y | ≤ D˙(k)−1Y · 1nY
∑nY
i=1 |z˙(k)i ||yi|, which is bounded since D˙(k)Y > 0, and by M since
E[|z(k)||y|] ≤ E[|z(k)|] 12E[|y|] 12 is bounded by Assumption 2.2(i). Hence, by Assumption 2.1(iii), and Lemmas A.1(ii)
and A.2, ‖R9n‖ ≤ OP (1) and ‖R10n‖ ≤ OP (n−
1
2
Z ) +OP (min(nZ , p)
−1). By identical arguments, ‖R11n‖ ≤ OP (1)
and ‖R12n‖ ≤ OP (n−
1
2
Z ) +OP (min(nZ , p)
−1).
Therefore, ||gˆn(θ)|| = OP (1) . For Part (ii), by T, ||gn(θ)|| ≤ ||gˆn(θ)||+ ||gˆn(θ)− gn(θ)|| = OP (1) by Part (i) and
Lemma A.3. 
Lemma A.7. Under Assumptions 2.1-2.3, (i) ||Gˆn|| = OP (1); (ii) ||Gn|| = OP (1).
Proof. Proof of Parts (i) and (ii) follow by identical arguments used for Proof of Lemma A.6. 
Lemma A.8. Under Assumptions 2.1-2.3, (i) ||Vˆ −1n || = OP (1); (ii) ||V −1n || = OP (1).
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Proof. Note that
Vˆn =
1
nZ
nZ∑
i=1
(1
p
Λˆ′zi
)(1
p
Λˆ′zi
)′
By CS,
||Vˆn|| ≤ 1
nZ
nZ∑
i=1
(1
p
p∑
k=1
‖λˆ(k)‖ · |z(k)i |
)(1
p
p∑
l=1
‖λˆ(l)‖ · |z(l)i |
)
≤
( 1
nZp
nZ∑
i=1
p∑
k=1
|z(k)i |2
)(1
p
p∑
k=1
‖λˆ(k)‖2
)
.
By T, CS, Assumption 2.1(iii), Lemmas A.1(ii) and A.2, for any k = 1, ..., p,
||λˆ(k)|| ≤ ||H−1|| · ||λ(k)||+ ||λˆ(k) −H−1λ(k)|| = OP (1) +OP (min(nZ , p)−1) +OP (n−
1
2
Z ).
Then, by Assumption 2.2(i) and M, ||Vˆn|| = OP (1). Now, by Lemma A.5, Vˆn is consistent for Vn. Let H? be the
probability limit of H has p → ∞, cf. Bai and Ng ([9], proof of Theorem 1, pp. 1599-1600). By Assumptions
2.1(ii), (iii), and WLLN, Vn
P→ H?−1ΣΛE[ff ′]ΣΛH?−1, which can be written as a product of r× r symmetric, p.d.
matrices, and therefore is invertible. Hence, Vˆn is invertible w.p.a.1.
For Part (ii), by CS,
‖Vn‖ ≤ ‖H−1‖2 ·
∥∥∥1
p
Λ′Λ
∥∥∥2 · ∥∥∥ 1
nZ
nZ∑
i=1
fif
′
i
∥∥∥
= OP (1),
where the equality follows by Lemma A.1(ii), Assumptions 2.1(ii), (iii), CS, and M, since ‖λ(k)‖ ≤ C, (k = 1, ..., p),
and E[‖f‖2] < C. Also, by the above arguments, Vn is invertible w.p.a.1. Hence, ||V −1n || = OP (1). 
Lemma A.9. Under Assumptions 2.1-2.3, gˆn(θ0) = gn(θ0) + oP (n
− 12
Y ).
Proof. By Proof of Lemma A.3, terms R3n and R4n from (A.2) are oP (n−
1
2
Y ) under Assumption 2.3(iii), so that
gˆn(θ0)− gn(θ0) = H−1 1
p
p∑
k=1
λ(k)
( 1
nY
nY∑
i=1
(e˙
(k)
i yi − E[e(k)y])− θ0
1
nX
nX∑
i=1
(e¨
(k)
i xi − E[e(k)x])
)
+H−1
1
p
p∑
k=1
λ(k)γ(k)
1
p
p∑
k=1
(λˆ(k) −H−1λ(k))
( 1
nY
nY∑
i=1
z˙
(k)
i yi − θ0
1
nX
nX∑
i=1
z¨
(k)
i xi
)
+ oP (n
− 1
2
Y )
:= R13n +R14n +R15n + oP (n−
1
2
Y ).
By CS,
‖R13n‖ ≤ 1√
nY p
· ‖H−1‖ ·
(∥∥∥ 1√
nY p
nY∑
i=1
p∑
k=1
λ(k)(e˙
(k)
i yi − E[e(k)y])
∥∥∥+ |θ0| · ∥∥∥ 1√
nXp
nX∑
i=1
p∑
k=1
λ(k)(e¨
(k)
i xi − E[e(k)x])
∥∥∥)
= OP (n
− 1
2
Y p
− 1
2 ) +OP (n
− 1
2
X p
− 1
2 )
= oP (n
− 1
2
Y ),
where the first equality follows by Lemma A.1(ii), Assumptions 2.3(v), (vi), and M. The second equality follows by
Assumption 2.3(iii) and p→∞.
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For bounding ‖R14n‖ and ‖R15n‖, we work through the two cases on rate restrictions from Assumption 2.3(iv).
Case 1: nY
/
min(nZ , p)
2 → 0.
By Assumption 2.3(iv), only a finite number of genetic variants are invalid instruments, so that
∑p
k=1 |γ(k)|2 = O(1).
Then, by CS and Assumptions 2.1(iii), 2.3(iv), ‖R14n‖ ≤ C · ‖H−1‖ · 1p
∑p
k=1 |γ(k)| = Op(p−1). Therefore, since
nY
/
min(nZ , p)
2 → 0 under Assumptions 2.3(iii) and 2.3(iv), ‖R14n‖ = oP (n−
1
2
Y ).
Using (A.1),
R15n = H ′ 1
p
p∑
k=1
( 1
nZ
nZ∑
i=1
fie
(k)
i
)( 1
nY
nY∑
i=1
z˙
(k)
i yi − θ0
1
nX
nX∑
i=1
z¨
(k)
i xi
)
+
( 1
nZ
nZ∑
i=1
fˆi(fi −H ′−1fˆi)′
)1
p
p∑
k=1
λ(k)
( 1
nY
nY∑
i=1
z˙
(k)
i yi − θ0
1
nX
nX∑
i=1
z¨
(k)
i xi
)
+
1
p
p∑
k=1
( 1
nZ
nZ∑
i=1
(fˆi −H ′fi)e(k)i
)( 1
nY
nY∑
i=1
z˙
(k)
i yi − θ0
1
nX
nX∑
i=1
z¨
(k)
i xi
)
:= R15nA +R15nB +R15nC .
Note that for any k = 1, ..., p, E[z(k)u] = λ(k)′E[fu] + E[e(k)u] = E[e(k)u], since E[fu] = 0. Hence, by CS,
‖R15nA‖ ≤ n−
1
2
Z n
− 1
2
Y ‖H‖ ·
(1
p
p∑
k=1
∥∥∥ 1√
nZ
nZ∑
i=1
fie
(k)
i
∥∥∥2) 12 (1
p
p∑
k=1
∣∣∣ 1√
nY
nY∑
i=1
(z˙
(k)
i yi − E[z(k)y])
∣∣∣2) 12
+n
− 1
2
Z n
− 1
2
X |θ0| · ‖H‖ ·
(1
p
p∑
k=1
∥∥∥ 1√
nZ
nZ∑
i=1
fie
(k)
i
∥∥∥2) 12 (1
p
p∑
k=1
∣∣∣ 1√
nX
nX∑
i=1
(z¨
(k)
i xi − E[z(k)x])
∣∣∣2) 12
+n
− 1
2
Z ‖H‖ ·
(1
p
p∑
k=1
∥∥∥ 1√
nZ
nZ∑
i=1
fie
(k)
i
∥∥∥2) 12 (1
p
p∑
k=1
|γ(k)|2
) 1
2
= OP (n
− 1
2
Z n
− 1
2
Y ) +OP (n
− 1
2
Z n
− 1
2
X ) +OP (n
− 1
2
Z p
− 1
2 ),
where the equality follows by Lemma A.1(i), Assumptions 2.1(vii), 2.2(i), 2.3(iv), CLT, and M.
Similarly, by CS,
‖R15nB‖ ≤ n−
1
2
Y
∥∥∥ 1
nZ
nZ∑
i=1
fˆi(fi −H ′−1fˆi)′
∥∥∥ · (1
p
p∑
k=1
‖λ(k)‖2
) 1
2 ·
(1
p
p∑
k=1
∣∣∣ 1√
nY
nY∑
i=1
(z˙
(k)
i yi − E[z(k)y])
∣∣∣2) 12
+n
− 1
2
X |θ0| ·
∥∥∥ 1
nZ
nZ∑
i=1
fˆi(fi −H ′−1fˆi)′
∥∥∥ · (1
p
p∑
k=1
‖λ(k)‖2
) 1
2 ·
(1
p
p∑
k=1
∣∣∣ 1√
nX
nX∑
i=1
(z¨
(k)
i xi − E[z(k)x])
∣∣∣2) 12
+
∥∥∥ 1
nZ
nZ∑
i=1
fˆi(fi −H ′−1fˆi)′
∥∥∥ · (1
p
p∑
k=1
‖λ(k)‖2
) 1
2 ·
(1
p
p∑
k=1
|γ(k)|2
) 1
2
= OP (min(nZ , p)
−1n
− 1
2
Y ) +OP (min(nZ , p)
−1n
− 1
2
X ) +OP (min(nZ , p)
−1p−
1
2 ),
where the equality follows by Lemma B.3 of Bai ([7], p.165), Lemma A.1(i), Assumptions 2.1(iii), 2.2(i), CS, CLT,
and M.
Using Lemma B.1 of Bai ([7], p.163), and similar arguments used to bound ‖R15nA‖, we have
‖R15nC‖ ≤ OP (min(nZ , p)−1n−
1
2
Y ) +OP (min(nZ , p)
−1n
− 1
2
X ) +OP (min(nZ , p)
−1p−
1
2 ),
by Lemma B.3 of Bai ([7], p.165), Assumptions 2.1(iii), 2.2(i), CS, CLT, and M.
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Therefore,
‖R15n‖ = OP (n−
1
2
Y p
− 1
2 ) +OP (n
− 1
2
X p
− 1
2 ) +Op(p
−1) +OP (n
− 1
2
Z n
− 1
2
Y ) +OP (n
− 1
2
Z n
− 1
2
X ) +OP (n
− 1
2
Z p
− 1
2 )
+OP (min(nZ , p)
−1n
− 1
2
Y ) +OP (min(nZ , p)
−1n
− 1
2
X ) +OP (min(nZ , p)
−1p−
1
2 ).
Under Assumptions 2.3(iii) and 2.3(iv), and nY
/
min(nZ , p)
2 → 0, ‖R15n‖ = oP (n−
1
2
Y ).
Since ‖R13n‖, ‖R14n‖, and ‖R15n‖ are oP (n−
1
2
Y ), gˆn(θ0)− gn(θ0) = oP (n
− 1
2
Y ).
Case 2: nY
/
min(nZ , p)
2 6→ 0.
By Assumption 2.3(iv), all genetic instruments are valid, so that γ(k) = 0, (k = 1, ..., p), and ‖R14n‖ = 0.
Now, using the same arguments as above for bounding ‖R15n‖, the terms that are a function of γ(k) are zero, so
that
‖R15n‖ = OP (min(nZ , p)−1n−
1
2
Y ) +OP (min(nZ , p)
−1n
− 1
2
X ) +OP (min(nZ , p)
−1n
− 1
2
Y ) +OP (min(nZ , p)
−1n
− 1
2
X )
+OP (min(nZ , p)
−1n
− 1
2
Y ) +OP (min(nZ , p)
−1n
− 1
2
X ).
Therefore, by Assumption 2.3(iii), terms ‖R13n‖, ‖R14n‖, and ‖R15n‖ are oP (n−
1
2
Y ), so that gˆn(θ0) − gn(θ0) =
oP (n
− 1
2
Y ). 
Lemma A.10. Under Assumptions 2.1-2.3, (i) σˆ2Y = σ
2
Y + oP (1); (ii) σˆ
2
X = σ
2
X + oP (1).
Proof. For trait y, the conditional trait variance estimate is given by
σˆ2Y = ˆvar(y)− βˆ′Y VˆnβˆY . (A.7)
Recall ˆvar(k)(y) = Dˆ
(k)
Y (σˆ
(k)2
Y + bˆ
(k)2
Y ). For any k = 1, ..., p,
1
nY
nY∑
i=1
(yi − bˆ(k)Y z˙(k)i )2 =
1
nY
nY∑
i=1
y2i + bˆ
(k)2
Y D˙
(k)
Y − 2bˆ(k)Y
1
nY
nY∑
i=1
z˙
(k)
i yi
=
1
nY
nY∑
i=1
y2i − bˆ(k)2Y D˙(k)Y .
Then, since σˆ
(k)2
mY =
1
nY
∑nY
i=1(yi − bˆ(k)Y z˙(k)i )2
/
nY D˙
(k)
Y , by the Assumption 2.3(ii),
1
nY
∑nY
i=1 y
2
i = ˆvar
(k)(y) + oP (1),
for each k = 1, ..., p. Hence, the median of ˆvar(k)(y) taken over k = 1, ..., p, the first term on the RHS of (A.7)
satisfies
ˆvar(y) =
1
nY
nY∑
i=1
y2i + op(1). (A.8)
Write βˆY = Vˆ
−1
n
1
p
Λˆ′DˆY bˆY . Then, ‖βˆY ‖ ≤ ‖Vˆ −1n ‖ · ‖ 1p Λˆ′DˆY bˆY ‖ = OP (1) by Lemma A.8(i), CS, and identical
arguments used to establish Lemma A.7(i). Similarly, for β¯Y = V
−1
n H
−1( 1
p
Λ′Λ
)
1
nY
∑nY
i=1 f˙iyi, ‖β¯Y ‖ = OP (1) by
Lemma A.8(ii), CS, and identical arguments used to establish Lemma A.7(ii). Since Vˆ −1n −V −1n = Vˆ −1n (Vn−Vˆn)V −1n ,
by CS, Lemmas A.5 and A.8, ‖Vˆ −1n − V −1n ‖ = oP (1).
Hence, by the above, and CS,
‖βˆY − β¯Y ‖ ≤ ‖Vˆ −1n − V −1n ‖ ·
∥∥∥1
p
Λˆ′DˆY bˆY
∥∥∥+ ‖V −1n ‖ · ∥∥∥1
p
Λˆ′DˆY bˆY −H−1
(1
p
Λ′Λ
) 1
nY
nY∑
i=1
f˙iyi
∥∥∥
= oP (1),
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since
∥∥ 1
p
Λˆ′DˆY bˆY −H−1
(
1
p
Λ′Λ
)
1
nY
∑nY
i=1 f˙iyi
∥∥ = oP (1) by identical arguments used for Proof of Lemma A.4.
Similarly,
‖βˆ′Y VˆnβˆY − β¯′Y Vnβ¯Y ‖ ≤ ‖βˆY ‖2 · ‖Vˆn − Vn‖+ ‖βˆY − β¯Y ‖ · ‖Vn‖ · ‖βˆY ‖+ ‖β¯Y ‖ · ‖Vn‖ · ‖βˆY − β¯Y ‖
= oP (1). (A.9)
Now,
β¯′Y Vnβ¯Y =
( 1
nY
nY∑
i=1
f˙iyi
)′(1
p
Λ′Λ
)
H ′−1V −1n VnV
−1
n H
−1
(1
p
Λ′Λ
)( 1
nY
nY∑
i=1
f˙iyi
)
=
( 1
nY
nY∑
i=1
f˙iyi
)′( 1
nZ
nZ∑
i=1
fif
′
i
)−1( 1
nY
nY∑
i=1
f˙iyi
)
. (A.10)
Then, for β˙Y =
(
1
nY
∑nY
i=1 f˙if˙
′
i
)−1( 1
nY
∑nY
i=1 f˙iyi
)
, by Assumption 2.3(i),
β¯′Y Vnβ¯Y − β˙′Y
( 1
nY
nY∑
i=1
f˙if˙
′
i
)
β˙Y = oP (1). (A.11)
Therefore, by (A.7), (A.8), (A.9), (A.10), and (A.11),
σˆ2Y =
1
nY
nY∑
i=1
y2i − β˙′Y
( 1
nY
nY∑
i=1
f˙if˙
′
i
)
β˙Y + oP (1),
so that σˆ2Y is asymptotically equivalent to the residual sum of squares, divided by the sample size, of the linear
regression f on y if f were known. Thus, σˆ2Y
P→ σ2Y . Part (ii) follows by identical arguments. 
Lemma A.11. Under Assumptions 2.1-2.3, if θˆ
P→ θ0, then Σˆ = Σ + oP (1).
Proof. Note that
‖Gˆ′nVˆ −1n Gˆn −G′nV −1n Gn‖ = ‖(Gˆn −Gn)′Vˆ −1n Gˆn +G′nVˆ −1n (Vn − Vˆn)V −1n Gˆn +G′nV −1n (Gˆn −Gn)‖
= oP (1),
by Lemmas A.4, A.5, A.7, A.8, and CS.
By Assumption 2.1(ii) and WLLN, G′nVnGn = E[fx]′E[ff ′]−1E[fx]+oP (1). Hence, by Assumptions 2.1(ii), 2.2(iii),
and T,
(Gˆ′nVˆ
−1
n Gˆn)
−1 = (E[fx]′E[ff ′]−1E[fx])−1 + oP (1). (A.12)
Also, by Assumption 2.3(iii), Lemma A.10, and Proposition 4.1(i),
σˆ2Y + θˆ
2cˆXY σˆ
2
X
P→ σ2Y + θ20cXY σ2X . (A.13)
By (A.12) and (A.13), Σˆ
P→ (E[fx]′E[ff ′]−1E[fx])−1(σ2Y + θ20cXY σ2X). 
A consistent estimator of the F-LIML standard error of θˆ is given by Σˆ
1
2n
− 12
Y , where Σˆ = (Gˆ
′
nΩˆn(θˆ)
−1Gˆn)−1,
and Gˆn = −p−1Λˆ′DˆX bˆX . This can be used to construct (1− α)-percent asymptotic confidence intervals
CISIML =
[
θˆ − ζα/2
√
Σˆ
nY
, θˆ + ζα/2
√
Σˆ
nY
]
,
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where ζα/2 is the (1 − α2 )-th quantile of the standard normal distribution. However, F-LIML confidence
intervals or tests based on the F-LIML standard errors will be valid only under strong identification of the
causal effect θ0.
A.3 Asymptotic distribution of F-LIML estimators under strong identification
Proof of Proposition 4.1(i): Consistency
By CS,
||Aˆn(θ)−An(θ)|| ≤ ||gˆn(θ)− gn(θ)|| · ||Vˆ −1n || · ||gˆn(θ)||
+||gn(θ)|| · ||Vˆ −1n − V −1n || · ||gˆn(θ)||
+||gn(θ)|| · ||V −1n || · ||gˆn(θ)− gn(θ)||.
Since Vˆ −1n − V −1n = Vˆ −1n (Vn − Vˆn)V −1n , ||Vˆ −1n − V −1n || = oP (1) by Lemmas A.5, A.8 and CS. Then, by Lemmas
A.3, A.6 and A.8, ||Aˆn(θ)−An(θ)|| = oP (1).
An(θ) can be simplified as
An(θ) =
( 1
nY
nY∑
i=1
f˙iyi − θ 1
nX
nX∑
i=1
f¨ixi
)′(1
p
Λ′Λ
)
H ′−1H ′
(1
p
Λ′Λ
)−1( 1
nZ
nZ∑
i=1
fif
′
i
)−1(1
p
Λ′Λ
)−1
H
×H−1(1
p
Λ′Λ
)( 1
nY
nY∑
i=1
f˙iyi − θ 1
nX
nX∑
i=1
f¨ixi
)
=
( 1
nY
nY∑
i=1
f˙iyi − θ 1
nX
nX∑
i=1
f¨ixi
)′( 1
nZ
nZ∑
i=1
fif
′
i
)−1( 1
nY
nY∑
i=1
f˙iyi − θ 1
nX
nX∑
i=1
f¨ixi
)
.
Under Assumptions 2.2(ii), 2.3(i), and 2.3(iv), yi = xiθ0 + ui (i = 1, ..., nY ). By WLLN and the law of iterated
expectations, 1
nY
∑nY
i=1 f˙iyi
P→ E[fy], 1
nX
∑nX
i=1 f¨xi
P→ E[fx], 1
nZ
∑nZ
i=1 fif
′
i
P→ E[ff ′], and 1
nY
∑nY
i=1 f˙iui
P→ E[fu] =
E[fE[u|f ]] = 0. Then,
An(θ) = E[fx]′E[ff ′]−1E[fx](θ − θ0)2 + oP (1).
Also, by Lemma A.10 and Assumption 2.3(iii), Bn(θ) = σ
2
Y +θ
2cXY σ
2
X+oP (1). Then, since Aˆn(θ) = An(θ)+oP (1),
by the above,
Qˆn(θ) =
E[fx]′E[ff ′]−1E[fx](θ − θ0)2
σ2Y + θ
2cXY σ2X
+ oP (1).
Now, for some positive constants κ1, κ2, κ3, let f(θ) = κ1(θ − θ0)2/(κ2 + κ3θ2). Then f is a smooth function of
θ with two stationary points; a global maximum and a global minimum. Note that ∇θf(θ) = 2κ1(θ − θ0)[κ2 +
κ3θθ0]/(κ2 + κ3θ
2)2, so that ∇θf(θ) = 0 only if θ = θ0 and θ = −κ2/(θ0κ3). Since f(−κ2/(θ0κ3)) > 0, f(θ) > 0
for all θ 6= θ0. Also note that f(θ0) = 0. Therefore, for any  > 0, there exists a constant C(θ0, ) > 0 such that
inf |θ−θ0|≥ f(θ) ≥ C(θ0, ).
Letting κ1 = E[fx]′E[ff ′]−1E[fx], κ2 = σ2Y and κ3 = cXY σ2X , we have that w.p.a.1, inf |θ−θ0|≥ Qˆn(θ) ≥ C(θ0, ),
since Qˆn(θ0)
P→ 0. Since Bn(θ) > 0 for all θ, Qˆn(θ) is continuous for all θ. Therefore θ¯ = arg min|θ−θ0|< Qˆn(θ)
exists and hence θˆ = θ¯ w.p.a.1. By standard arguments (see Newey [36]), θ¯
P→ θ0, giving consistency. 
Proof of Proposition 4.1(ii): Asymptotic normality
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The first-order condition for θˆ satisfies ∇θQˆn(θˆ) = 0. Some simple calculations yield
∇θQˆn(θ) = 2Gˆ
′
nVˆ
−1
n gˆn(θ)
σˆ2Y + θ
2cˆXY σˆ2X
− 2gˆn(θ)
′Vˆ −1n gˆn(θ)(θcˆXY σˆ
2
X)
(σˆ2Y + θ
2cˆXY σˆ2X)
2
(A.14)
and
∇θθQˆn(θ) = 2Gˆ
′
nVˆ
−1
n Gˆn
σˆ2Y + θ
2cˆXY σˆ2X
− 2cˆXY σˆ
2
X gˆn(θ)
′Vˆ −1n gˆn(θ)
(σˆ2Y + θ
2cˆXY σˆ2X)
2
− 4θcˆXY σˆ
2
X
σˆ2Y + θ
2cˆXY σˆ2X
· ∇θQˆn(θ). (A.15)
The first term on the RHS of (A.14) satisfies
2Gˆ′nVˆ
−1
n gˆn(θ)
σˆ2Y + θ
2cˆXY σˆ2X
=
2(Gn + oP (1))
′(V −1n + oP (1))gˆn(θ)
σˆ2Y + θ
2cˆXY σˆ2X
=
2G′nV
−1
n gˆn(θ)
σˆ2Y + θ
2cˆXY σˆ2X
+ oP (gˆn(θ))
=
2G′nV
−1
n gˆn(θ)
σ2Y + θ
2cXY σ2X
+ oP (gˆn(θ)),
where the first term follows by Lemma A.4, and noting that Vˆ −1n −V −1n = Vˆ −1n (Vn−Vˆn)V −1n , so that ||Vˆ −1n −V −1n || =
oP (1) by CS, Lemmas A.5 and A.8. The second term follows by Lemmas A.7, A.8, A.10, and M, and the third
term follows by Lemma A.10.
Using similar arguments for the other terms on the RHS of (A.14) and (A.15),
∇θQˆn(θ) = 2G
′
nV
−1
n gˆn(θ)
σ2Y + θ
2cXY σ2X
+OP (gˆn(θ))
2 + oP (gˆn(θ)) + oP (gˆn(θ))
2 (A.16)
and
∇θθQˆn(θ) = 2G
′
nV
−1
n Gn
σ2Y + θ
2cXY σ2X
+ oP (1) +OP (gˆn(θ))
2 + oP (gˆn(θ))
2 +OP (∇θQˆn(θ)). (A.17)
Now, since H−1
(
1
p
Λ′Λ)E[fu] = 0,
gn(θ0) = n
− 1
2
Y H
−1(1
p
Λ′Λ
)( 1√
nY
nY∑
i=1
(f˙iyi − E[fy])− cˆ
1
2
XY θ0
1√
nX
nX∑
i=1
(f¨ixi − E[fx])
)
(A.18)
= OP (n
− 1
2 ), (A.19)
by Lemmas A.1(ii), Assumptions 2.1(iii), 2.3(i), 2.3(iii), S, CLT, and M.
By the first-order conditions and mean value theorem, for some θ¯ between θˆ and θ0,
∇θQn(θ0) +∇θθQn(θ¯)(θˆ − θ0) = 0. (A.20)
By (A.14)− (A.20), Lemma A.9, noting that ∇θQn(θ¯) = OP (n−
1
2
Y ) by the first-order conditions, and ∇θθQn(θ¯) =
∇θθQn(θ0) + oP (1) for any estimator θ¯ P→ θ0,
(
G′nV
−1
n Gn+oP (1)
)√
nY (θˆ−θ0) = −G′nV −1n H−1
(1
p
Λ′Λ
)( 1√
nY
nY∑
i=1
(f˙iyi−E[fy])−cˆ
1
2
XY θ0
1√
nX
nX∑
i=1
(f¨ixi−E[fx])
)
+oP (1).
By WLLN and Assumption 2.3(iii), note that this simplifies to
(
E[fx]′E[ff ′]−1E[fx]+oP (1)
)√
nY (θˆ−θ0) = −E[fx]′E[ff ′]−1
( 1√
nY
nY∑
i=1
(f˙iyi−E[fy])−c
1
2
XY θ0
1√
nX
nX∑
i=1
(f¨ixi−E[fx])
)
+oP (1).
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By Assumption 2.2(iii), E[fx]′E[ff ′]−1E[fx] is invertible, so that
√
nY (θˆ − θ0) = −(E[fx]′E[ff ′]−1E[fx])−1E[fx]′E[ff ′]−1
(
1 −θ0c
1
2
XY
)( 1√
nY
∑nY
i=1(f˙iyi − E[fy])
1√
nX
∑nX
i=1(f¨ixi − E[fx])
)
+ oP (1)
D→ N
(
0,
σ2Y + θ
2
0cXY σ
2
X
E[fx]′E[ff ′]−1E[fx]
)
,
where the last line follows by CLT and S. 
Proof of Proposition 4.1(iii): Consistent asymptotic variance estimation
see Lemma A.11.
A.4 Asymptotic distribution of F-AR, F-LM, and F-CLR statistics under
weak identification
Let H? be the probability limit of H as p → ∞, cf. Bai and Ng ([9], proof of Theorem 1, pp. 1599-
1600). Let Ω = H?−1ΣΛE[ff ′]Σ′ΛH?−1′ ⊗ (σ2Y + θ20cXY σ2X), ∆G = H?−1ΣΛE[ff ′]Σ′ΛH?−1′ ⊗ θ0cXY σ2X ,
and ∆GG = H
?−1ΣΛE[ff ′]Σ′ΛH?−1′ ⊗ cXY σ2X .
Lemma A.12. Under Assumptions 2.1, 2.2(i),(ii), 2.3, and 2.4, for G˜n = Gˆn − ∆ˆG(θ0)Ωˆn(θ0)−1gˆn(θ0),
√
nY
(
gˆn(θ0)
G˜n −G?
)
D→ N
((
0
0
)
,
(
Ω 0′r×r
0r×r ∆GG −∆′GΩ−1∆G
))
.
Proof. We can write
Gˆn = −H−1 1
p
p∑
k=1
λ(k)
( 1
nX
nX∑
i=1
z¨
(k)
i xi
)
− 1
p
p∑
k=1
(λˆ(k) −H−1λ(k))
( 1
nX
nX∑
i=1
z¨
(k)
i xi
)
−H−1 1
p
p∑
k=1
λ(k)(Dˆ
(k)
X − D¨(k)X )bˆ(k)X −
1
p
p∑
k=1
(λˆ(k) −H−1λ(k))(Dˆ(k)X − D¨(k)X )bˆ(k)X
:= −H−1 1
p
p∑
k=1
λ(k)
( 1
nX
nX∑
i=1
z¨
(k)
i xi
)
− T2n − T3n − T4n
where ‖T3n‖ and ‖T4n‖ are oP (n−
1
2
Y ) by identical arguments used to bound terms R3n and R4n in Proof of Lemma
A.3.
By CS,
‖T2n‖ ≤
(1
p
p∑
k=1
‖λˆ(k) −H−1λ(k)‖2
) 1
2
(1
p
p∑
k=1
∣∣∣ 1
nX
nX∑
i=1
z¨
(k)
i xi
∣∣∣2) 12 .
Note that E[z(k)x] = λ(k)′E[ff ′]βX + λ(k)′E[fE[eX |f ]] + E[e(k)f ′]βX + γ(k)X = OP (n
− 1
2
Y ) by Assumptions 2.1(ii),
(iii), (vii), 2.2(ii), 2.4(i),(ii), CS, and M. Hence, by M and Lemma A.2, ‖T2n‖ = oP (n−
1
2
Y ).
Thus,
Gˆn = −H−1
(1
p
Λ′Λ
)( 1
nX
nX∑
i=1
f¨ixi
)
−H−1 1
p
p∑
k=1
λ(k)
( 1
nX
nX∑
i=1
e¨
(k)
i xi
)
+ oP (n
− 1
2
Y ).
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By Assumption 4.2(ii), 1
p
∑p
k=1 |γ(k)X | = o(n
− 1
2
Y ), so that by CS, M, Lemma A.1 and Assumption 2.1(iii), the second
term on the RHS is bounded by
‖H−1‖ · C · 1
p
p∑
k=1
∣∣∣ 1
nX
nX∑
i=1
e¨
(k)
i xi
∣∣∣ = oP (n− 12Y ).
Therefore,
Gˆn = −H−1
(1
p
Λ′Λ
)( 1
nX
nX∑
i=1
f¨ixi
)
+ oP (n
− 1
2
Y ).
Thus, for G = −H−1( 1
p
Λ′Λ
)
E[fx], we can write( √
nY gˆn(θ0)√
nY (G˜n −G)
)
=
(
Ir 0r×r
−∆ˆ′GΩˆ(θ0)−1 Ir
)( √
nY gˆn(θ0)√
nY (Gˆn −G)
)
+ oP (1).
By Lemma A.9, gˆn(θ0) = gn(θ0) + oP (n
− 1
2
Y ), so that by Assumption 2.3(i), up to oP (1) terms,
Cov(
√
nY gˆn(θ0),
√
nY Gˆn) = Cov
(
H−1
(1
p
Λ′Λ
)( 1
nY
nY∑
i=1
f˙iyi − θ0cˆ
1
2
XY
1
nX
nX∑
i=1
f¨ixi
)
,−H−1
(1
p
Λ′Λ
)
×
(
cˆ
1
2
XY
1
nX
nX∑
i=1
f¨ixi
))
= H−1
(1
p
Λ′Λ
)( 1
nX
nX∑
i=1
V ar(f¨ixi)
)(1
p
Λ′Λ
)′
H−1′ ⊗ θ0cˆXY
= ∆G,
where the last equality follows by H
P→ H?, Assumptions 2.1(ii), 2.2(i), and 2.3(i), (iii).
By Assumptions 2.1(ii), (iii), 2.2(ii), 2.3(iii), Lemmas A.3 and A.10, Ωˆn(θ0)
P→ Ω, ∆ˆG(θ0) P→ ∆G, and ∆ˆGG P→ ∆GG.
The result then follows by S, and identical arguments used in Proof of Proposition 4.1(ii). 
Proof of Proposition 4.2: Asymptotic distribution of identification-robust test statistics under the
null
The proof of the result closely follows Proof of Theorem 3.2 of Smith ([42], p.252; also see [26]), and is given
here for completeness. In the proof of Lemma A.12, we have established that Ωˆn(θ0)
P→ Ω, ∆ˆG(θ0) P→ ∆G, and
∆ˆGG
P→ ∆GG. Hence, by S, and Lemma A.12, S˜ D→ ZS ∼ N(0, Ir), T˜ D→ ZT ∼ N(G, Ir), and S˜ and T˜ are
(asymptotically) mutually independent.
Let ∆ = ∆GG −∆′GΩ−1∆G, and ∆ˆ = ∆ˆGG − ∆ˆG(θ0)′Ωˆn(θ0)−1∆ˆG(θ0). Under H0 : θ = θ0, ARn = S˜′S˜ D→ χ2(r).
For the F-LM test statistic, write LMn =
(
nY G˜
′
n∆ˆ
− 1
2 Ωˆ(θ0)
− 1
2 gˆn(θ0)
)2/
(nY G˜
′
n∆ˆ
−1G˜n). Now, nY G˜′n∆ˆ
− 1
2 Ωˆ(θ0)
− 1
2
×gˆn(θ0) D→ Z ′TZS . Given ZT , Z ′TZS ∼ N(0,Z ′TZT ), and therefore Z ′TZS
/
(Z ′TZT )
1
2 ∼ N(0, 1) and hence is
independent of Z ′TZT . Therefore, as nY G˜′n∆ˆ−1G˜n D→ Z ′TZT , LMn D→ χ2(1).
For the F-CLR statistic, write
CLRn = 1
2
(
ARn − nY G˜′n∆ˆ−1G˜n +
√(ARn − nY G˜′n∆ˆ−1G˜n)2 + 4LMn(nY G˜′n∆ˆ−1G˜n))
D→ 1
2
(
Z ′SZS −Z ′TZT +
√
(Z ′SZS −Z ′TZT )2 + 4(Z ′TZS)2
)
.
Since Z ′SZS = (Z ′TZS)2
/Z ′TZT + (Z ′SZS − (Z ′TZS)2/Z ′TZT ) can be decomposed into independent χ2(1) and
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χ2(r − 1) random variables respectively, independent of Z ′TZT , conditionally on ZT ,
CLRn D→ 1
2
(
χ2(1) + χ2(r − 1)−Z ′TZT +
√
(χ2(1) + χ2(r − 1)−Z ′TZT )2 + 4χ2(1)(Z ′TZT )
)
,
as required. 
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